Prevention of CMV disease after cardiac transplantation

Prevention of CMV disease after cardiac transplantation refers to prophylactic or preemptive intervention against cytomegalovirus infection and clinical disease in patients undergoing heart transplantation Due to therapeutic immunosuppression, these recipients are vulnerable to primary infection or reactivation of latent CMV, with the highest risk occurring in seronegative recipients receiving an organ from a seropositive donor

Due to therapeutic immunosuppression, these recipients are vulnerable to primary infection or reactivation of latent CMV, with the highest risk occurring in seronegative recipients receiving an organ from a seropositive donor Pathophysiologically, active CMV replication can cause systemic CMV syndrome, tissue-invasive disease such as myocarditis, hepatitis, or pneumonitis, and significant indirect complications including acute allograft rejection and accelerated cardiac allograft vasculopathy

Pathophysiologically, active CMV replication can cause systemic CMV syndrome, tissue-invasive disease such as myocarditis, hepatitis, or pneumonitis, and significant indirect complications including acute allograft rejection and accelerated cardiac allograft vasculopathy

Pathophysiologically, active CMV replication can cause systemic CMV syndrome, tissue-invasive disease such as myocarditis, hepatitis, or pneumonitis, and significant indirect complications including acute allograft rejection and accelerated cardiac allograft vasculopathy